Autopsy report · NCT02855164
Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)
Cause of deathNo reason given
Life of this trial
- Ran for about 3 years 8 months before it stopped.
- 350 participants enrolled.
- Results were posted on the registry 1 year 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Non-alcoholic Steatohepatitis (NASH)
- Interventions
- Tropifexor (LJN452); Placebo
- Participants
- 350
- Sites
- 81
- Countries
- Argentina, Australia, Austria, Belgium, Canada, France, Germany, India, Italy, Japan, Netherlands, Singapore and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.